Commercialization: Page 28
-
PharmaVoice Team/PharmaVoice
Commercialization Strategies in Rare Diseases
Agency Partners Simply Can’t Fake It. Over the course of my career working in pharmaceutical advertising, one of the most common refrains I’ve heard through the years from eager agency folks is: “We need to get into oncology or rare diseases." I have to admit that it’s a declaration that always m...
By David M. Paragamian • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
A Patient-Focused Approach to Rare Diseases - Connecting with Multiple Stakeholders
In order to successfully commercialize a rare disease product, manufacturers must consider the needs of multiple stakeholders. Adding to the challenge, each stakeholder may have unique needs. This creates increased complexity when marketing a therapy in the rare disease space, but also offers mul...
By David Schneider • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Tired of “innovation“ yet? No doubt that innovation is one of those “buzz-tion" words — transformation, collaboration, disruption — that some might deride as having been used so frequently that it has lost some of its inherent value as an action-based, momentum-driving movement. I say nay. Innova...
By Taren Grom • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Upfront
Merck Expands Donation Program Merck has expanded the Mectizan Donation Program (MDP) to reach an additional 100 million people a year through 2025 as part of its global effort to eliminate lymphatic filariasis (LF). Through the MDP, established by Merck in 1987, the company donates Mectizan for ...
By PharmaVoice Team • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Last Word
Supporting Caregivers Scott Williams, VP, Head of Global Patient Advocacy and Strategic Partnerships, EMD Serono, talks about the company’s efforts to recognize and support unpaid caregivers. PV: What is the Embracing Carers program and EMD Serono’s role? Williams: Embracing Carers is a global m...
By Scott Williams • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Disruptive Advertising
Technology disruptions in our world are becoming routine, and consumers are becoming impervious to the daily assault on their attention. In order to be effective, brand marketers need to rise above and beyond an ever-rising bar of campaign creativity, as well as use technology to break through al...
By PharmaVoice Team • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Pricing Front and Center
Pharmaceutical pricing is a complex — and often controversial — issue impacting all stakeholders in healthcare. Discussions around value, fair pricing, transparency, outcomes, and patient affordability are front and center as companies try to provide some insight, but each stakeholder in this gro...
By Denise Myshko • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Social Media: Taking the Plunge: Pharma and Social Media
Pharmaceutical companies are increasingly embracing social media as a forum for reaching patients. For example, 40% of adults use social media for health-related issues, such as connecting with patients with similar issues. Social forums allow pharmaceutical companies to not only engage with cons...
By PharmaVoice Team • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
"I Want My Brand on Social!"
Social media is ubiquitous. Everyone is on it in some capacity. We are all hands-on experts; but social is very nuanced. How do I leverage creative, messaging, audience, device, time of day, etc., to connect with my customers? A successful start requires focus on a strategy—one that is as individ...
By Joe Youssef • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Transcending Traditional Social Media: From Awareness to Uncovering Actionable Insights
It goes without saying that social media is one of the most widely used forms of communication today. Pharmaceutical companies are trying to “crack the code" and understand how to effectively use this channel to achieve organizational initiatives while complying with rigorous industry regulations...
By Dr. Theodore Search • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Industry Gears Up For Track and Trace
Counterfeit medicines have taken a huge toll, both in terms of human costs as well as financially. Interpol estimates that 1 million deaths each year can be linked to counterfeits. According to PwC, counterfeit pharmaceuticals are a $200 billion-plus annual business. The problem is most severe in...
By Kim Ribbink • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Red Zone: Applying User Experience Design to Develop Effective Patient Suport
Treatment nonadherence is a complex behavior that requires much more than a simple one-size-fits-all approach to address the challenge. What can pharma learn from the behavioral sciences to deliver patient support that is effective in improving tx adherence? Health psychology and behavioral econo...
By Kate Perry • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Warp Speed Ahead It’s that time of year again — time to pause, reflect, and take stock of the year that was, while gearing up for the wild ride that lies ahead. This time last year, we had just elected a new president, and today there remains quite a bit of uncertainty as to what President Trump...
By Taren Grom • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Upfront
Pfizer Service Provides Social Workers for Patients Pfizer Oncology Together is a first-of-its-kind offering for patients taking Pfizer Oncology medicines. The program offers dedicated social workers called “Care Champions" to help navigate the complexities that accompany treatment, such as ident...
By PharmaVoice Team • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
HealthTech
LivaNova Receives FDA Approvals for SenTiva Device for Treatment of Epilepsy Trend Watch: Health Technology Increases Wellness Across Epilepsy, Autism, and Weight Loss LivaNova, a market-leading medical technology company, has received FDA approval for its latest vagus nerve stimulation therapy (...
By PharmaVoice Team • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Last Word
Digital Health Initiatives Georgia Mitsi, Senior Director, Search Evaluation & Digital Health Care Initiatives, at Sunovion Pharmaceuticals, discusses the company’s digital health efforts. PV: What is the driving force behind the many digital health initiatives at Sunovion? Mitsi: Sunovion’s ...
By Georgia Mitsi • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: What Does the Future Hold?
We tasked the PharmaVOICE 100 community of industry executives to think about some of the most important trends they expect will challenge the status quo, move the industry forward, and contribute to breakthroughs in medicine and business models. Their thoughtful insights signal the multitude of ...
By PharmaVoice Team • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Agile Marketing
Agile methodology is all about leveraging experiences and failures to improve a process, and has been adopted across industries and entities to organize everything from software development to household chores and family activities. Rooted in IT, the agile manifesto has been adopted by winemakers...
By Robin Robinson • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Alternative Delivery
Point and click — could ordering your prescription drugs be as easy as that? Some experts say yes, some say we’ll see. But there is one thing for sure: the retail pharmacy world is changing. And one disrupter — Amazon — is in the middle of it all. And with Amazon’s mass distribution system, the e...
By Taren Grom • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Artificial Intelligence
Artificial intelligence (AI) in health represents a collection of multiple technologies, enabling machines to sense, comprehend, act, and learn so they can perform administrative and clinical healthcare functions. There are different applications of AI and machine learning in pharma, including di...
By Taren Grom • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Bioethics
New technologies for gene editing have created excitement about the potential for cures for diseases, as well as debates around ethics and regulatory oversight that are sure to dominate this field of science for years to come. CRISPR-Cas9, the newest gene-editing tool, is getting a lot of attenti...
By Denise Myshko • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Brand Engagement
As patients start to manage their health through digital devices, not only does the pharma industry need to be more patient-centric, but the brand story must focus on the patient and his or her journey to create true brand engagement. According to a report from DRG Digital, as the pharmaceutical ...
By Robin Robinson • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Pipeline Disrupters
In recent years, several therapeutic disruptors have hit the market, pushing aside current standard treatment protocols. From hepatitis C cures to immuno-oncology therapies, recent approvals have upended how diseases are treated, providing patients with significant advances. Pharmaceutical, biote...
By PharmaVoice Team • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Rare Diseases
In recent years, a growing number of companies have entered the rare disease space, bolstered by regulatory incentives, such as the Orphan Drug Act, and scientific breakthroughs. While each rare disease has a relatively small patient population — defined in the United States as affecting fewer th...
By Kim Ribbink • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Real-World Outcomes
Real-word outcomes is not a new trend by any means, but it’s a market-changing model that is coming into its own and worthy of covering. That’s because the pharmaceutical market continues to shift to an outcomes-based reimbursement system, driven by payers’ need to rein in rising drug prices, adv...
By Denise Myshko • Nov. 20, 2017
Previous
